Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Colm, Farrell"'
Autor:
Maria Pitsiu, Özkan Yalkinoglu, Colm Farrell, Pascal Girard, Cristina Vazquez‐Mateo, Orestis Papasouliotis
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1157-1169 (2023)
Abstract B cell stimulating factor (BLyS) and a proliferation‐inducing ligand (APRIL) are targets for novel treatments in patients with systemic lupus erythematosus (SLE). Atacicept is a recombinant, soluble fusion protein that blocks BLyS and APRI
Externí odkaz:
https://doaj.org/article/9efaa86ce0bd41dbb6749afefe027a5e
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 5, Pp 719-723 (2023)
Abstract Maribavir was approved by the US Food and Drug Administration for the treatment of patients aged ≥12 years and weighing ≥35 kg with posttransplant cytomegalovirus infection/disease refractory (with/without resistance) to valganciclovir,
Externí odkaz:
https://doaj.org/article/1bb20c6241bb43d38deb38ea719dd7b1
Publikováno v:
The Journal of Clinical Pharmacology. 63:593-603
This study aimed to develop a population pharmacokinetic (PK) model of ambrisentan in pediatric patients (8-18 years) with pulmonary arterial hypertension (PAH) and compare pediatric ambrisentan systemic exposure with previously reported adult data.
Publikováno v:
Pediatric Research.
Background Iron deficiency is the primary cause of anemia in children. Intravenous (IV) iron formulations circumvent malabsorption and rapidly restore hemoglobin. Methods This Phase 2, non-randomized, multicenter study characterized the safety profil
Publikováno v:
Annals of Allergy, Asthma & Immunology. 126:707-712
BACKGROUND Recombinant human C1 esterase inhibitor (rhC1-INH) is indicated in the United States for the treatment of acute hereditary angioedema (HAE) attacks in adolescents and adults; it is also indicated in Europe for children aged 2 years and old
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Acumapimod, an investigational oral p38 mitogen-activated protein kinase inhibitor for treatment during severe acute exacerbations of chronic obstructive pulmonary disease, is metabolized primarily by cytochrome P450 3A4 (CYP3A4) and is a P-glycoprot
Publikováno v:
Transplantation and Cellular Therapy. 28:S368-S369
Aims: To develop a population pharmacokinetic (PK) model of ambrisentan in paediatric patients aged 8 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2eb73c64f93ca497379568e9078827a3
https://doi.org/10.22541/au.162191011.16279819/v1
https://doi.org/10.22541/au.162191011.16279819/v1
Autor:
Brian M. Sadler, Franck Skobieranda, Maria Pitsiu, Colm Farrell, Michael J. Fossler, David A. Burt, David G. Soergel
Publikováno v:
The Journal of Clinical Pharmacology. 58:762-770
Oliceridine is a novel G protein-biased ligand at the μ-opioid receptor that differentially activates G protein coupling while mitigating β-arrestin recruitment. Unlike morphine, oliceridine has no known active metabolites; therefore, analgesic eff
Autor:
Colm Farrell, Ofer Spiegelstein, Alena Y. Edwards, Anna Elgart, Laura Rabinovich-Guilatt, Ofra Barnett-Griness
Publikováno v:
British Journal of Clinical Pharmacology. 83:1932-1943
Aims Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. This meta-analysis evaluated the population pharmacokinetics (PK)